197 related articles for article (PubMed ID: 25228518)
1. [Synthetic lethality as a functional tool in basic research and in anticancer therapy].
Toma M; Skorski T; Sliwiński T
Postepy Hig Med Dosw (Online); 2014 Sep; 68():1091-103. PubMed ID: 25228518
[TBL] [Abstract][Full Text] [Related]
2. Application of the concept synthetic lethality toward anticancer therapy: a promise fulfilled?
Canaani D
Cancer Lett; 2014 Sep; 352(1):59-65. PubMed ID: 23962561
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Lethal Interactions in Cancer Therapy.
Geng X; Wang X; Zhu D; Ying S
Curr Cancer Drug Targets; 2017; 17(4):304-310. PubMed ID: 27113746
[TBL] [Abstract][Full Text] [Related]
4. Harnessing synthetic lethal interactions in anticancer drug discovery.
Chan DA; Giaccia AJ
Nat Rev Drug Discov; 2011 May; 10(5):351-64. PubMed ID: 21532565
[TBL] [Abstract][Full Text] [Related]
5. Systematic analysis of cancer-specific synthetic lethal interactions provides insight into personalized anticancer therapy.
Guo L; Dou Y; Xiang Y; Luo L; Xu X; Wang Q; Zhang Y; Liang T
FEBS J; 2023 Mar; 290(6):1531-1548. PubMed ID: 36181326
[TBL] [Abstract][Full Text] [Related]
6. The concept of synthetic lethality in the context of anticancer therapy.
Kaelin WG
Nat Rev Cancer; 2005 Sep; 5(9):689-98. PubMed ID: 16110319
[TBL] [Abstract][Full Text] [Related]
7. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
[TBL] [Abstract][Full Text] [Related]
8. A lethal combination for cancer cells: synthetic lethality screenings for drug discovery.
Ferrari E; Lucca C; Foiani M
Eur J Cancer; 2010 Nov; 46(16):2889-95. PubMed ID: 20724143
[TBL] [Abstract][Full Text] [Related]
9. DNA Double Strand Break Repair - Related Synthetic Lethality.
Toma M; Skorski T; Sliwinski T
Curr Med Chem; 2019; 26(8):1446-1482. PubMed ID: 29421999
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic synthetic lethality approaches in cancer therapy.
Yang H; Cui W; Wang L
Clin Epigenetics; 2019 Oct; 11(1):136. PubMed ID: 31590683
[TBL] [Abstract][Full Text] [Related]
11. Syn-lethality: an integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies.
Li XJ; Mishra SK; Wu M; Zhang F; Zheng J
Biomed Res Int; 2014; 2014():196034. PubMed ID: 24864230
[TBL] [Abstract][Full Text] [Related]
12. Embracing synthetic lethality of novel anticancer therapies.
Kamal A; Shaik TB; Malik MS
Expert Opin Drug Discov; 2015 Oct; 10(10):1119-32. PubMed ID: 26211783
[TBL] [Abstract][Full Text] [Related]
13. Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.
Kacsinta AD; Dowdy SF
Expert Opin Biol Ther; 2016; 16(2):161-72. PubMed ID: 26630128
[TBL] [Abstract][Full Text] [Related]
14. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.
Topatana W; Juengpanich S; Li S; Cao J; Hu J; Lee J; Suliyanto K; Ma D; Zhang B; Chen M; Cai X
J Hematol Oncol; 2020 Sep; 13(1):118. PubMed ID: 32883316
[TBL] [Abstract][Full Text] [Related]
15. Development of synthetic lethality anticancer therapeutics.
Fang B
J Med Chem; 2014 Oct; 57(19):7859-73. PubMed ID: 24893124
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibition as a prototype for synthetic lethal screens.
Liu X
Methods Mol Biol; 2013; 986():123-37. PubMed ID: 23436410
[TBL] [Abstract][Full Text] [Related]
17. The role of drug-metabolizing enzymes in synthetic lethality of cancer.
Zeng Z; Zheng W; Hou P
Pharmacol Ther; 2022 Dec; 240():108219. PubMed ID: 35636517
[TBL] [Abstract][Full Text] [Related]
18. Synthetic lethality on drug discovery: an update on cancer therapy.
Yar MS; Haider K; Gohel V; Siddiqui NA; Kamal A
Expert Opin Drug Discov; 2020 Jul; 15(7):823-832. PubMed ID: 32228106
[TBL] [Abstract][Full Text] [Related]
19. Development of synthetic lethality in cancer: molecular and cellular classification.
Li S; Topatana W; Juengpanich S; Cao J; Hu J; Zhang B; Ma D; Cai X; Chen M
Signal Transduct Target Ther; 2020 Oct; 5(1):241. PubMed ID: 33077733
[TBL] [Abstract][Full Text] [Related]
20. An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development.
van Pel DM; Barrett IJ; Shimizu Y; Sajesh BV; Guppy BJ; Pfeifer T; McManus KJ; Hieter P
PLoS Genet; 2013; 9(1):e1003254. PubMed ID: 23382697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
